news releases

08 April 2020

OncoImmune Receives FDA Approval for COVID-19 Clinical Trial

OncoImmune, Inc. has received a study-may-proceed letter from the FDA for its Phase III clinical trial testing the safety and efficacy of CD24Fc for the treatment of hospitalized COVID-19 patients (SAC-COVID). A cohort of 230…
Read more...
24 February 2020

Institute of Human Virology and OncoImmune Launch Clinical Trial to Lessen Effects of HIV Later in Infection

On February 1, the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) and OncoImmune, Inc. launched a new Phase II clinical trial called CALIBER, which will test whether OncoImmune’s lead product,…
Read more...
27 January 2020

OncoImmune Announces Presentation of CD24Fc Phase IIa Data and Phase III Clinical Trial Design at the 2020 Transplantation & Cellular Therapy Meetings

OncoImmune, Inc. announced today that clinical data from its Phase IIa clinical trial of CD24Fc are being presented at the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Meeting, taking place in Orlando,…
Read more...
30 December 2019

OncoImmune Announces Approval of IND Application for ONC-392 – The anti-CTLA-4 Antibody that Preserves CTLA-4 Recycling for Better Safety and Efficacy

OncoImmune, Inc. announced today that its Investigational New Drug (“IND”) application for ONC-392, its novel, next generation anti-CTLA-4 antibody, has been approved by the U.S. Food and Drug Administration (“FDA”). The IND approval enables OncoImmune…
Read more...
30 July 2018

OncoImmune, Inc. Receives $2 million Grant through the FDA’s Orphan Products Clinical Trials Grants Program

OncoImmune, Inc. received a $2,000,000 grant through the FDA’s Orphan Products Clinical Trials Grants Program to support the phase IIB study of CD24Fc for the prevention of graft-versus-host disease in leukemia patients undergoing hematopoietic stem…
Read more...
17 December 2017

OncoImmune Doses Final Patient in CD24Fc Phase IIA Clinical Trial

OncoImmune, Inc. today announced the dosing of the final patient in the phase IIA clinical trial testing the safety and efficacy of CD24Fc in leukemia patients undergoing hematopoietic stem cell transplantation. When the last patient…
Read more...

About Us

Based in Rockville, Maryland, OncoImmune is a
privately-held, clinical-stage biopharmaceutical
company that is actively engaged in the discovery
and development of biopharmaceuticals for the
treatment of cancer and autoimmune disease.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.